Merck & Co. stock gains on Japan approval for Keytruda QLEX

Merck & Co. stock (ISIN US58933Y1055) is trading near recent highs after Japan’s Ministry of Health, Labor and Welfare approved the company’s Keytruda QLEX subcutaneous formulation on September 21, 2026, adding a more convenient dosing option for its flagship immuno-oncology therapy. As of September 21, 2026, the shares changed hands around USD 148 on the New York Stock Exchange, keeping Merck among the larger healthcare names by market value.

Japan approval strengthens Keytruda QLEX franchise

According to Fidelity on September 21, 2026, Merck announced that Japan’s Ministry of Health, Labor and Welfare approved KEYTRUDA QLEX injection for subcutaneous use for all indications of intravenous Keytruda already authorized in Japan, broadening patients’ access to the drug. The company highlighted that subcutaneous administration can shorten chair time and offer a more convenient option compared with standard infusion, which is strategically important as Keytruda remains one of Merck’s largest revenue contributors.

As MarketBeat reported on September 21, 2026, the update was categorized as an approval event for KEYTRUDA QLEX, underlining that regulators now accept the subcutaneous combination of pembrolizumab and berahyaluronidase for the same set of solid tumor indications as intravenous Keytruda. For investors, this means Merck can defend and potentially expand its oncology franchise with a new formulation rather than a new molecule, an important distinction in terms of development cost and speed to market.

Stock trades near recent highs with strong run-up

Per price data as of September 21, 2026, Merck & Co. stock traded at about USD 148 on the New York Stock Exchange, compared with a recent closing level of USD 146.87 that was reported for the prior trading session on September 20, 2026, implying a daily gain of roughly 0.8% as investors reacted to the regulatory news in Japan. Over the last year, the shares have climbed close to 40% from levels around USD 105, moving the stock nearer to its 52-week high in the mid-150s and leaving it well above a 52-week low in the low-100s, a performance that stands out against many broader healthcare benchmarks.

According to MarketScreener, Merck & Co. shares most recently closed at USD 146.87, while the average analyst price target compiled there stands at USD 152.96, indicating an upside of around 4.1% from that close. This places the current price of roughly USD 148 in the lower half of the range between the recent closing level and the average target, suggesting that a portion of the expected appreciation has already materialized but that analysts still see room for further gains.

Fundamentals and analyst views remain supportive

According to GuruFocus on September 21, 2026, Merck’s dividend yield stands at about 2.31% with a three-year dividend growth rate of 5.4%, reflecting the company’s willingness to return cash to shareholders while still investing heavily in its pipeline. The same analysis notes a payout ratio a little above one on a trailing basis, a signal that management will need continued earnings growth from products like Keytruda and newer assets to keep dividend increases sustainable over the medium term.

As TipRanks reported on September 21, 2026, Morgan Stanley analyst Terence Flynn maintained a Buy rating on Merck with a price target of USD 179.00 after the stock closed at USD 146.87, implying a potential upside of around 21.9%. The same report cites an average analyst price target of USD 160.40 and characterizes the consensus rating as Moderate Buy, meaning the current price around USD 148 trades about 8.5% below that consensus level and noticeably under the more optimistic Morgan Stanley target.

Risks highlighted by valuation concerns

However, not every observer is enthusiastic about the current valuation of Merck & Co. stock. According to Seeking Alpha on September 21, 2026, one analyst downgraded Merck from a Buy to a Sell rating after the shares delivered a total return of roughly 92% since June 2025 and pushed the platform’s Quant Valuation Grade from A to D. That analysis argues that investor enthusiasm around Merck’s collaboration on an mRNA-based melanoma vaccine has driven the stock into overbought territory and suggests waiting for a correction of 15% to 25% toward a range of USD 110 to USD 125 into early 2027 before considering new positions.

Balancing these views, the current setup for Merck & Co. stock combines a solid fundamental story anchored by oncology and vaccine franchises with a valuation that some see as rich relative to historical levels. For investors, the key numbers to watch now are the pace of revenue and earnings growth over the next few quarters and the extent to which new formulations like Keytruda QLEX can offset rising competition in immuno-oncology and potential pricing pressure in major markets.

Merck & Co. stock price snapshot

As of intraday trading on September 21, 2026, Merck & Co. stock traded at approximately USD 148.05 on the New York Stock Exchange, compared with the prior close of USD 146.87, representing a daily increase of about 0.81% at that point in the session. With a market capitalization in the high-USD-370-billion range based on this price level, the company sits firmly among the largest constituents of the S&P 500 healthcare sector, and its share price remains closer to its 52-week high than to its 52-week low.

More news and analyses on Merck & Co. stock